Fig. 4.

Changes in different intron-retaining MAPT RNA species between individuals without dementia and patients with AD. (a-c) Relative RNA copy number of different intron-retaining MAPT species, TIR³-MAPT (a), TIR¹²-MAPT (b), and TIR³⁺¹²-MAPT (c), measured by ddPCR normalised with β-tubulin (TubB). (d-h) Absolute RNA levels measured in copies per nanogram of RNA of TIR³-MAPT (d), TIR¹²-MAPT (e), TIR³⁺¹²-MAPT (f), total-MAPT (g), and β-tubulin (h). (i-j) Relative RNA copy number ratios of different intron-retaining MAPT species, TIR³-MAPT/TIR¹²-MAPT (i), TIR³-MAPT/TIR³⁺¹²-MAPT (j), and TIR¹²-MAPT/TIR³⁺¹²-MAPT (k), measured by ddPCR. (l-n) Percentage of different intron-retaining MAPT species, TIR³-MAPT (l), TIR¹²-MAPT (m) and TIR³⁺¹²-MAPT (n), with respect to total-MAPT RNA copy number. Graphs show results of samples from frontal lateral cortex in orange (FLC: n = 10 control subjects and 26 patients with Alzheimer's disease, AD) and hippocampus in green (HPC: n = 10 control subjects and 23 patients with Alzheimer's disease, AD). Two-way ANOVA test was done to rule out interaction between variables and t-test analysis was performed to examine the differences between the means of two groups using Welch's correction when unequal variances or Mann–Whitney test when data distribution was non-Gaussian, and equal variance or Kolmogorov–Smirnov test when unequal variances. Scatter plot graphs show error-bars representing 95% confidence intervals (CI) and the corresponding P-values when P < 0.05.